760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors

• Kim Margolin,
• Victoria Atkinson,
• Charlotte Lemech,
• Philippe Bedard,
• Przemyslaw Twardowski,
• Sajeve Thomas,
• Amy Prawira,
• Arash Yavari,
• Peter Lloyd,
• Warren Brenner,
• Rosemina Merchant,
• Carole Galligan,
• Fahar Merchant,
• Minh D To,
• Melissa Coello,
• Jesus Fuentes Antras,
• Sudhir Madduri Karanam,
• Matthen Mathew

Affiliations

Kim Margolin

Medical Oncology, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California, USA

Victoria Atkinson

University of Queensland, and Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Woolloongabba, Queensland, Australia

Charlotte Lemech

Aff5 Scientia Clinical Research Sydney Australia

Philippe Bedard

Aff46 0000 0001 2150 066Xgrid.415224.4Princess Margaret Cancer Centre Toronto ON Canada

Przemyslaw Twardowski

7Saint John’s Cancer Institute, Providence Saint John’s Health Center, Santa Monica, CA, USA

Sajeve Thomas

MD Anderson Cancer Center Orlando, Orlando, Florida, USA

Amy Prawira

Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent’s Hospital, Sidney, New South Wales, Australia

Arash Yavari

Conquest Hospital, Cardiology Department, The Ridge, East Sussex, TN37 7RD, UK

Peter Lloyd

6KinDyn Consulting Ltd., London, UK

Warren Brenner

Lynn Clinical Research Institute, Boca Raton, Florida, USA

Rosemina Merchant

Medicenna Therapeutics, Toronto, ON, Canada

Carole Galligan

Research and Development, Medicenna Therapeutics Inc, Toronto, Ontario, Canada

Fahar Merchant

Medicenna Therapeutics, Toronto, ON, Canada

Minh D To

Medicenna Therapeutics, Toronto, ON, Canada

Melissa Coello

1Medicenna Therapeutics, Toronto, Canada

Jesus Fuentes Antras

3Princess Margaret Hospital, Toronto, ON, Canada

Sudhir Madduri Karanam

1Medicenna Therapeutics, Toronto, ON, Canada

Matthen Mathew

4Boca Raton Regional Hospital, Boca Raton, FL, USA